Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GGT1 | P19440 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL29743138 | 1.00 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL19030830 | 1.00 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL25878 | 0.96 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL25877 | 0.96 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL4834297 | 0.96 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL11851702 | 0.96 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL29743139 | 0.96 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL2993825 | 0.93 | KDM4E (0.61) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL2993829 | 0.93 | KDM4E (0.61) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL4094492 | 0.91 | KDM4E (0.53) | KDM4EHSD17B10HPGDALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131645-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2023-07-13 | — | — | WO | claimed |
| CN-110114333-B | Improved synthesis of lysine acetylsalicylate glycine particles | 阿斯皮亚尔股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| EP-3558920-B1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2021-04-07 | — | — | EP | claimed |
| EP-3558920-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | Ventaleon GmbH (DE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115434-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | VENTALEON GMBH (DE) | 2018-06-28 | — | — | WO | claimed |
| WO-2023131645-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131645-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| CN-110114333-B | Improved synthesis of lysine acetylsalicylate glycine particles | 阿斯皮亚尔股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-110114333-B | Improved synthesis of lysine acetylsalicylate glycine particles | 阿斯皮亚尔股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-110114333-B | Improved synthesis of lysine acetylsalicylate glycine particles | 阿斯皮亚尔股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-3558920-B1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10882811-B2 | Synthesis of lysine acetylsalicylate glycine particles | ASPIAIR GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| WO-2018115434-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | VENTALEON GMBH (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115434-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | VENTALEON GMBH (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017109037-A1 | TREATMENT OF MODERATE TO SEVERE INFLUENZA | VENTALEON GMBH (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-9492413-B2 | Use of salt of an acetylsalicylic acid for the treatment of viral infections | VENTALEON GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| EP-2249866-B1 | USE OF AN ACETYLSALICYLIC ACID SALT FOR THE TREATMENT OF VIRAL INFECTIONS | ACTIVAERO GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120017892-A1 | USE OF SALT OF AN ACETYLSALICYLIC ACID FOR THE TREATMENT OF VIRAL INFECTIONS | ACTIVAERO GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2249866-A2 | USE OF AN ACETYLSALICYLIC ACID SALT FOR THE TREATMENT OF VIRAL INFECTIONS | Activaero GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089822-A2 | USE OF AN ACETYLSALICYLIC ACID SALT FOR THE TREATMENT OF VIRAL INFECTIONS | ACTIVAERO GMBH (DE) | 2009-07-23 | — | — | WO | disclosed |